Pyrimidine derivatives for treatment of hyperproliferative disorders

US7582645B2 · kind B2 · utility

Assignee

• Bayer Pharmaceuticals Corporation · US

Inventors

• Julie A. Dixon · Bethany, US
• Dhanapalan Nagarathnam · Bethany, US
• Lei Zhang · Beijing, CN
• Chunguang Wang · Hamden, US
• Lin Yi · Berkeley Heights, US
• Yuanwei Chen · Sichuan, CN
• Jianqing Chen · New Haven, US
• Brian Bear · Oceanside, US
• Michael Brands · Hamden, US
• Alexander Hillisch · Solingen, DE
• Donald Bierer · Daly City, US
• Ming Wang · Montgomery, US
• Wenlang Fu · Milford, US
• Martin F. Hentemann · Boulder, US
• Ann-Marie Bullion · Milford, US

Key dates

• Filing date: Oct 8, 2004
• Grant date: Sep 1, 2009
• Expiry date: Dec 19, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D453/02
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Pyrimidine derivatives of formula (I) in which J and Y represent aromatic or heteroaromatic rings; R2, G, G′, and G″ represent substituent groups and R2a represents H or halogen; L represents a linking group; and M represents CH or N. Pharmaceutical compositions containing these compounds, and methods of using these compounds in treatment of hyperproliferative diseases such as cancer are also disclosed and claimed.